See the Glossary for more terms.
ISARG Review and Assessment
Yes. Foreign institutions are required to have NIAID representatives review their laboratories that conduct NIAID-funded select agent research. The laboratory review, which includes a laboratory visit, is to determine if the safety standards are comparable to those required for U.S. institutions that propose to use, possess, or transfer select agents. This review is required every three years following the initial review. Get an overview of the approval process in the Flowchart for NIAID Select Agent Research Awards (PowerPoint).
To conduct NIAID-funded select agent research, foreign institutions must provide information satisfactory to NIAID that safety, security, incident response, personnel security risk assessment, records, and training measures are in place comparable to those described in 42 CFR Part 73 (go to National Select Agent Registry Regulations).
NIAID-supported researchers abroad must comply with NIH grants policy, which includes research requirements of the U.S. and the researcher's country, providing the foreign requirements do not contradict U.S. laws.
Though some research partners overseas may have concerns about complying with research requirements of the U.S, others have found our policies helpful. For example, researchers in non-U.S. labs may view the CDC laboratory visit as a resource for improving the biosafety and biosecurity of their laboratories. (However, NIH cannot provide additional funding if the report identifies deficiencies.)
The U.S. Congress, which funds NIH, expects appropriated dollars to be spent and programs to be executed lawfully. Further, NIAID is helping to ensure that its funded researchers conduct their work safely and securely.
Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, U.S. institutions that perform research with select agents must be inspected for biosafety and biosecurity. These inspections provide for a level of safety and security to prevent unwarranted access to pathogenic organisms and toxins and ensure a negligible risk to the public.
Until WHO develops worldwide biosafety and biosecurity standards, NIAID requires a review, including a visit, of foreign sites performing research that involves select agents.
The grantee institution's signing official and the responsible official (or alternate) from the foreign institution must certify that the facility meets the local institution's requirements, which must be equivalent to those of U.S. institutions, for working safely with select agents.
NIAID does not impose U.S. law on foreign institutions. The purpose is to ensure safety, security, and responsibility of all parties.
Laboratory visits are required for foreign laboratories receiving NIAID awards. U.S. government employees with experience in select agent research or policy review reports of laboratory visits along with the select agent policies of the foreign institution.
If they find deficiencies based on CDC requirements (or USDA requirements in the case of plants and animals), the review group can recommend a restriction on the award, prohibiting funding until issues are resolved.
A U.S. PI should consult an NIAID program officer and grants management specialist before making changes. Some changes require prior approval, especially changes in scope.
A permit from CDC or USDA is required for transporting select agents in the U.S. A permit issued to a domestic institution does not apply to a project's foreign subcomponent.
For international sites receiving NIH funds, transportation procedures and requirements must be equivalent to those for U.S. institutions. For NIAID projects, the grantee institution's signing official and the responsible official (or alternate) from the foreign institution are responsible for compliance with local and international requirements for transporting select agents.
The awardees are responsible for their subcomponents' and subcontractors' compliance with select agent policy and requirements. Though not part of the site visit team, the U.S. awardee is involved in all communication with the foreign subcontractor and helps ensure that information is submitted as quickly as possible.
The quickest communication occurs when the subcontractor works directly with staff in NIAID's Office of Research Training and Special Programs to prepare documents for submission. The U.S. investigator is copied on all correspondence but can choose to have all information go through him or her, which may slow down the process.
If the application is selected for funding, the applicant must notify his or her program officer that the proposed research includes restricted experiments, based on his or her knowledge of the subject and the definition of restricted experiments described in Section 13 of 42 CFR Part 73, 7 CFR Part 331, and 9 CFR Part 121. For the most recent links to the regulations, go to Select Agents Regulations on the National Select Agent Registry Web site.
No. Send them to NIAID after you get your Notice of Award. We prefer that you send them as a complete package, but if that is not possible or would cause significant delays, send the completed APHIS/CDC Form 1 with the signature of the responsible institutional official as soon as possible.
The foreign institution translates rules and regulations into English.
A CDC site visit team acting on behalf of NIAID will organize a laboratory visit, which will occur after we receive a completed APHIS/CDC Form 1, and the responsible official and PI agree on a date. There will be two or three persons on a team, depending on the complexity of the laboratories and number of different select agents at the site.
If you are working in the same laboratory in the same location, your laboratory (along with your institution's select agents policies) needs a review only once for the Ebola projects. If you begin research with a different agent, you will need second laboratory visit.
An initial site visit is required for each new award; subsequent visits are conducted every three years. If awardees propose to use a new select agent or laboratory, a follow-up visit may occur sooner.
Once issues are resolved, a second visit may be needed, depending on the nature of the deficiencies. If a second visit is necessary, the site visit team needs eight to ten weeks before a return visit (HHS requires eight weeks' notice).
CDC Select Agent Program staff determine the team for the site visit. There is no guarantee it will be the same team. Teams ensure consistency by using the same standards at every site in every country.
The shortest possible time between receipt of the Notice of Award and the laboratory visit is 10 weeks, assuming that the foreign site completes and submits the laboratory application form immediately after receipt of the notice and has no scheduling delays.
Background checks are the responsibility of the foreign institution as part of its personnel security risk assessments.
Foreign institutions must submit their procedure for personnel background checks or the comparable personnel security risk assessment procedure for clearing people who have access to select agents in NIAID-funded research to NIAID's Office of Research Training and Special Programs. The procedure must be signed by the institution's signing official.
Interagency Select Agent Review Group (ISARG) members include U.S. federal employees who have experience in select agent research or policies. Members include NIH scientific program, grants, and contracts staff along with employees from the CDC, Department of Justice, Department of State, and other appropriate federal agencies. The committee meets about three times a year.
ISARG recommends to NIAID whether a restriction on research involving select agents should be removed from an award.
The final decision on what is "sufficient" is based on a group decision made by ISARG members. The group has sufficient information and freedom to make a thoughtful and informed recommendation. The recommendation is sent to NIAID's Division of Extramural Activities director for approval.
The rules, policies, and laws of the foreign institution are assessed along with the laboratory visit report for similarity to U.S. requirements.
ISARG reviews foreign institutions for comparable select agent requirements for registration, security risk assessments, safety plans, security plans, emergency response plans, training, transfers, record keeping, laboratory inspections, and notifications.
ISARG checks that foreign laboratories have facilities that meet minimum biosafety and biosecurity requirements. Managers at foreign institutions who disagree with the site visit team's evaluations can provide additional information or clarification for ISARG review.
Foreign institutions that do not have a process similar to the one described in 42 CFR Part 73 (go to National Select Agent Registry) should provide information about applicable laws, regulations and policies, safety, security, training, and procedures to ensure that only approved and appropriate persons (approved by the foreign institution) have access to select agents.
ISARG discusses the information provided and determines what is sufficient and how much leeway can be permitted. Every situation will be considered separately but with a goal of establishing some consistency in approach.
Expensive surveillance equipment is not a requirement for award, but you must have minimum biosafety and biosecurity procedures. If the laboratory visit report indicates the paper tracking system and padlocks are sufficient, that is all the laboratory needs to do.
Once your institution submits a completed APHIS/CDC Form 1 application, the site visit team leader will contact the PI or responsible institutional official. The team leader can answer questions about the requirements. For further information, go to the National Select Agent Registry.
No. There are no certifications for foreign institutions. Rather, NIAID informs foreign institutions that they have been approved to use NIH funds for select agent work. This approval is valid for three years.
Yes. All foreign laboratories and institutions are required to have their select agent policies (or comparable policies) reviewed by ISARG.
Email email@example.com with the title of this page or its URL and your question or comment. We answer questions by email and post them here. Thanks for helping us clarify and expand our knowledge base.
Last Updated January 09, 2013
Last Reviewed January 09, 2013